Our impact

Throughout 2024, together with our ministry of health partners, we supported the delivery of 30 million treatments, reaching 21.3 million people at risk of parasitic disease in six countries.

This year, a significant milestone was achieved through our shared leadership role in the Pediatric Praziquantel Consortium (PPC). For the first time globally, a new paediatric treatment for SCH was delivered to pre-school aged children (PSAC) in Uganda and Côte d’Ivoire.

In September 2024, a historic moment was marked in Zanzibar, where the 12 billionth dose of albendazole (ALB)—an essential treatment for LF and intestinal worms donated by GSK—was delivered during a ceremony attended by Her Royal Highness (HRH) the Duchess of Edinburgh. The event highlighted Unlimit Health’s enduring partnership with Zanzibar’s MoH, which contributed to reducing SCH prevalence from 50% to under 2%.

Throughout the year, we engaged closely with MoH and research partners to carry out treatment impact assessments and CES across seven countries. These efforts are designed to generate high-quality data to inform programme performance and guide future treatment strategies.

We also continued to support national partners in enhancing the quality and performance of treatment programmes through robust data collection and evaluation efforts.